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Abstract In the folate cycle MTHFD1, encoded by MTHF
D1, is a trifunctional enzyme containing 5,10-methylenetetra-
hydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate
cyclohydrolase and 10-formyltetrahydrofolate synthetase ac-
tivity. To date, only one patient with MTHFD1 deficiency,
presenting with hyperhomocysteinemia, megaloblastic anae-
mia, hemolytic uremic syndrome (HUS) and severe combined
immunodeficiency, has been identified (Watkins et al J Med
Genet 48:590–2, 2011). We now describe four additional pa-
tients from two different families. The second patient present-
ed with hyperhomocysteinemia, megaloblastic anaemia,
HUS, microangiopathy and retinopathy; all except the reti-
nopathy resolved after treatment with hydroxocobalamin, be-
taine and folinic acid. The third patient developed megaloblas-
tic anaemia, infection, autoimmune disease and moderate liver
fibrosis but not hyperhomocysteinemia, and was successfully
treated with a regime that included and was eventually re-
duced to folic acid. The other two, elder siblings of the third
patient, died at 9 weeks of age with megaloblastic anaemia,
infection and severe acidosis and had MTFHD1 deficiency
diagnosed retrospectively. We identified a missense mutation
(c.806C>T, p.Thr296Ile) and a splice site mutation
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(c.1674G>A) leading to exon skipping in the second patient,
while the other three harboured a missense mutation
(c.146C>T, p.Ser49Phe) and a premature stop mutation
(c.673G>T, p.Glu225*), all of which were novel. Patient fi-
broblast studies revealed severely reduced methionine forma-
tion from [14C]-formate, which did not increase in cobalamin
supplemented culture medium but was responsive to folic and
folinic acid. These additional cases increase the clinical spec-
trum of this intriguing defect, provide in vitro evidence of
disturbed methionine synthesis and substantiate the effective-
ness of folic or folinic acid treatment.
Introduction
Transfer of single-carbons (1C) is an essential part of many
cellular processes, including de novo nucleotide synthesis,
methylation and production of methionine (Rosenblatt and
Fenton 2001). Amajor carrier of 1C-units is folate, in the form
of tetrahydrofolate (THF). THF-mediated 1C metabolism is
compartmentalised between the nucleus, mitochondria and
cytoplasm. In the mitochondria, the balance of the pathway
is towards production of formate, which is then shuttled to the
cytoplasm (Tibbetts and Appling 2010). Cytoplasmic formate
is reattached to THF for production of purines, or for further
processing to 5,10-methylene-THF for dTMP synthesis or to
5-methyl-THF for methionine synthesis (Tibbetts and Appling
2010; Watkins and Rosenblatt 2012; see Fig. 1). In the
cytoplasm, the first three reactions of the attachment and re-
duction of formate on THF are catalysed by the trifunctional
enzyme, MTHFD1. These reactions include: the ATP-
dependent conversion of formate and THF to 10-formyl-
THF (synthetase); the interconversion of 10-formyl-THF
and 5,10-methenyl-THF (cyclohydrolase); and the NADP-
dependent reduction of 5,10-methenyl-THF to 5,10-methy-
lene-THF (dehydrogenase) (Fox and Stover 2008). In addition
to dTMP production via thymidylate synthase, 5,10-methy-
lene-THF is further processed either to 5-methyl-THF by
MTHFR to act as a carbon donor in methionine synthesis, or
used by serine hydroxymethyltransferase (SHMT) to produce
serine from glycine.
A number of very rare inborn errors of folate uptake
and metabolism have been described. Hereditary folate
malabsorption and glutamate-formiminotransferase deficien-
cy may cause megaloblastic anaemia and neurological
damage without, or with only mild, hyperhomocysteinemia.
In contrast, MTHFR deficiency causes severe hyperhomo-
cysteinemia and neurological abnormalities without defects
of hematopoiesis. Biochemical changes in cerebral folate
deficiency are localised to CSF only with no anaemia
(Watkins and Rosenblatt 2012). Mild impairments to one-
carbon metabolism, due to insufficient folate or SNPs in
genes involved in folate or cobalamin metabolism, are also
associated with many pathologies, including neural tube
defects (Brody et al 2002; De Marco et al 2002; Parle-
McDermott et al 2006), cancers (Stevens et al 2007;
Wang et al 2007) and cardiovascular disease (Christensen
et al 2009; Shaw et al 2009). It is therefore not surprising
that a gene-disruption of Mthfd1 is embryonically lethal in
mice (MacFarlane et al 2009). Deletion of Mthfd1l and
Mthfd2, two mitochondrial homologs of Mthfd1, the first
of which catalyses only the synthetase reaction and the
second both the cyclohydrolase and dehydrogenase in the
developing embryo, are also embryonically lethal in murine
models (Di Pietro et al 2002; Momb et al 2013),
underlining the requirement of this activity for the growing
organism.
Thus far, only one patient with MTHFD1 deficiency has
been identified (Keller et al 2013; Watkins et al 2011). The
2 months old infant presented with elevated homocysteine,
megaloblastic anaemia, atypical hemolytic uremic syn-
drome (HUS) and severe combined immune deficiency
(SCID). The patient was compound heterozygous for two
mutations in MTHFD1, one affecting a splice acceptor site
in intron 8 and the other changing a critical arginine resi-
due in the NADP-binding site. Here, we report four new
patients with MTHFD1 deficiency caused by compound
heterozygosity of a missense mutation with either a splice
site or nonsense mutation and demonstrate a defect in fi-
broblast methionine formation using synthesis from [14C]-
formate.
Fig. 1 The cytoplasmic folate cycle. Formate is attached to THF to begin
the cycle. The three steps catalysed by MTHFD1 (FTHFS, MTHFC and
MTHFD) are boxed in solid lines. Folinic acid (5-formyl-THF) can enter
the cycle after conversion to 5,10-methenyl-THF. The endpoints
methionine and serine are boxed in dashed lines. FTHFS, 10-
f o r m y l t e t r a h y d r o f o l a t e s y n t h e t a s e ; MTHFC , 5 , 1 0 -
methenyltetrahydrofolate cyclohydrolase;MTHFD, 5,10-methylenetetra-
hydrofolate dehydrogenase;MTHFS, 5,10-methenyltetrahydrofolate syn-
thetase;MTHFR, 5,10-methylenetetrahydrofolate reductase;MS, methio-
nine synthase; SHMT, serine hydroxymethyltransferase; THF,
tetrahydrofolate
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Materials and methods
Cell culture
Skin fibroblasts, obtained for diagnostic purposes, were used
for molecular and biochemical evaluation and were grown in
Earle’s minimum essential medium supplemented with 10 %
FCS with antibiotics (Suormala et al 2004).
Sequencing
For patient 2, RNA and genomic DNA were extracted from
cultured skin fibroblasts or blood spots using the QIAamp
RNeasy Mini Kit and the QIAamp DNA Mini Kit (Qiagen),
respectively. The RT-PCR reaction was performed using the
One-Step RT-PCR Kit (Qiagen) following the manufacturer’s
instructions. Genomic DNA PCR was performed using HOT
FIREPol DNA Polymerase (Solis BioDyne) and direct se-
quencing of all exons and flanking intronic sequences of
MTHFD1 was performed. Primer pairs designed to amplify
the complete MTHFD1 open reading frame in five reactions
(fragments) were used. Sequencing was performed using
BigDye Terminator v1.1 Cycle Sequencing kit and analysed
on a 3500 or 3130xl Genetic Analyzer according to the man-
ufacturer’s instructions (Applied Biosystems). Cell treatment
for NMD inhibition was performed by incubating cultured
fibroblast with 100 μl/ml cycloheximide (Sigma-Aldrich) for
4 h. All primer sequences are available upon request.
For patient 3, whole-exome sequencing (WES) was carried
out using Illumina HiSeq 2000 high-throughput sequencing
technology. Agilent SureSelect HumanAll Exon 51M kit was
used for exome capture. Quality assessment of the sequence
reads was performed by generating QC statistics with FastQC
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). Read
alignment to the reference human genome (hg19, UCSC
assembly, February 2009) was done using BWA (Burrow-
Wheeler alignment) with default parameters (Li and Durbin
2009). After removal of PCR duplicates using Picard tools,
(http://picard.sourceforge.net) and file conversion using
SAMtools (Li et al 2009), quality score recalibration, indel
realignment and variant calling were performed with the
Genome Analysis Toolkit package (McKenna et al 2010).
After excluding all dbSNPs, we focused our search for
potential pathogenic mutations on the coding regions and
splice sites of genes related to folate metabolism fitting an
autosomal recessive mode of inheritance. Mutations
identified by WES were verified by Sanger sequencing.
For patients 4 and 5, DNAwas extracted from dried blood
spots derived from neonatal metabolic screening using the
QIAamp DNA Mini Kit (QIAGEN), with confirmation of
MTHFD1mutations by PCR and Sanger sequencing of exons
3 and 8.
Specific enzyme assays
Cobalamin coenzyme synthesis was determined as described
previously (Jusufi et al 2014). Incorporation of [14C]-propio-
nate was assayed by a slight modification of the method al-
ready described (Willard et al 1976). 5,10-Methylenetetrahy-
drofolate reductase (MTHFR) activity was assayed in its phys-
iological forward direction using the natural substrates 5,10-
methylenetetrahydrofolate and NADPH and the cofactor FAD
as described earlier (Suormala et al 2002). Formation of [14C]-
methionine and [14C]-serine from [14C]-formate was deter-
mined as described earlier (Fowler et al 1997) with fibroblasts
cultured for 72 h in normal medium or supplemented with
OHCbl (1 mg/L: ∼1 μM; Sigma), 5-formyl-THF (folinic acid,
100 μM; Sigma) or folic acid (100 μM; Sigma). Assays were
performed as duplicates in at least two independent
experiments.
Statistics
Statistical significance was determined using an unpaired two-
tailed Student’s t-test with a cut-off of p<0.05 unless other-
wise indicated. Statistics were performed and graphs generat-




This patient has been described (Keller et al 2013; Watkins
et al 2011).
Patient 2
An 18 month-old girl, the first child of non-consanguineous
French parents, presented with asthenia, vomiting and icteric
skin. Findings of anaemia, schizocytosis (9/00) and
thrombopenia indicated atypical hemolytic uremic syndrome
(HUS) withmicroangiopathy and severe arterial hypertension,
although renal function was normal. There was no evidence of
post-diarrheic HUS or other known causes of atypical HUS,
such as activation of complement factors or alternative path-
way pro t e i n s . Bone mar row ana lys i s r evea l ed
dyserythropoietic and megaloblastic anaemia (Table 1). Leu-
kopenia (2.7×109/L) and haptoglobin of less than 0.06 g/L
were also noted. Serum cobalamin, transcobalamin and unsat-
urated cobalamin binding capacity of total serum were nor-
mal, as was serum folate. However, free (21 μmol/L; normal:
30–50) and total carnitine (39 μmol/L; normal: 43–65) was
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slightly decreased, and analysis of amino and organic acids
revealed hyperhomocysteinemia and low normal methionine,
while methylmalonic acid was normal (Table 1).
Treatment was initiated with hydroxocobalamin (OHCbl;
1 mg/day p.o. and 1 mg/day i.m.), folinic acid (5 mg/day p.o.)
and betaine (600 mg x6/day p.o.) along with antihypertensive
drugs. Red blood cell and platelet transfusions were started
and repeated at short intervals. Response to treatment was
slow but complete and transfusions and antihypertensive
drugs were stopped after 3 months after which plasma homo-
cysteine was <15 μmol/L and methionine 97 μmol/L.
Following treatment, psychomotor development and cere-
bral MRI were found to be normal at 6 years of age. However,
convergent strabism has been noted since the age of 6 months.
Despite the continued normalisation of methionine and homo-
cysteine values an electroretinogram showed bilateral alter-
ations due to progressive maculopathy with retinal atrophy
which have worsened over the years and are unresponsive to
the treatment that has been adapted over time. At 8 years of
age, the patient receives OHCbl (1 mg/day p.o. and 1 mg/
week i.m.), folinic acid (2× 5 mg/day) and betaine (2× 1 g/
day). However, CSF 5-methyl-THFmeasured at 6 and 7 years
of age revealed low values (26 and 34, nmol/L, respectively;
control values >44 nmol/L), which did not normalise when
folinic acid was increased to 2× 5 mg/day (CSF 5-methyl-
THF at 8 years: 34 nmol/L).
Patients 3–5
Cases 3, 4 and 5 are from the same non-consanguineous fam-
ily of Swedish origin. One previous child was healthy. Al-
though born after patients 4 and 5, patient 3 was the index
case in whom mutations in MTHFD1 were identified. This
diagnosis was confirmed in patients 4 and 5 retrospectively.
Case 3 A girl, born at 42 weeks gestation, birth weight
2950 g, was monitored closely because of her siblings’ med-
ical history. Haematological investigations at 4 days of life
showedmacroblastic bonemarrowwith a slight megaloblastic
appearance, consistent with cobalamin or folate deficiency,
and marked anisocytosis; however, blood haemoglobin
(Hgb; 205 g/L), MCV (109 fL) and leukocyte counts were
normal over the first week of life. Platelets were high a few
hours after delivery (464*109/L) and increasing.
Intensive metabolic investigation at 12 days of age showed
blood and urinary lactate levels mostly within normal limits.
Cobalamin and folate levels in blood were normal and high,
respectively. Plasma amino acids were normal, with methio-
nine at 20–55 μmol/L; plasma homocysteine (10 μmol/L) and
urinary organic acids were normal.
At 9 weeks of age, anaemia (Hgb 78 g/L) and MCV rising
to 108 fL was noted. Treatment with cobalamin and folic acid
(5 mg/day) was started without obvious results after 2 days.
Thiamine responsive megaloblastic anaemia (TRMA) was
suspected and parenteral thiamine was added to the existing
treatment, with an immediate response in reticulocyte counts,
Hgb, and MCV, seeming to confirm this diagnosis. After a
further 6 weeks of treatment, at the age of 4 months, Hgb
and MCV had normalised and folic acid and cobalamin treat-
ment was terminated. Bone marrow was then almost normal-
ised with normoblastic erythropoiesis and normal
myelopoiesis.
At 7 months the girl fell ill with fever, a mononucleosis-like
finding in the throat, and obstructive bronchitis. Anaemia
(Hgb 78 g/L) but normal MCV was found. A general inflam-
matory state developed with high C-reactive protein levels,
increasing immunoglobulins, high serum acute phase pro-
teins, serum albumin decreasing to 16 g/L (normal 36–50)
together with low prothrombin index. Serum lactate dehydro-
genase was 19.8 μkat/L (normal <7.5). Auto-antibodies with
high titres against DNA and striatedmuscle appeared and anti-
nuclear antibodies were positive. Serum transaminases were
only marginally elevated. Serum titers against several viruses
were high but regarded as non-specific. Bone marrow was
again macro-megaloblastic with anisocytosis and disturbed
myelopoiesis and a liver biopsy showed a low grade
lympho-histiocytic inflammation in portal areas and in lobuli.
The girl was treated with blood transfusions, gamma globulin
infusions, corticosteroids, and cobalamin and folic acid were
reintroduced. Reticulocyte counts and Hgb improved rapidly,
bone marrow ameliorated and inflammatory markers normal-
ised slowly. The treatment with cobalamin and folic acid was
terminated after 2 weeks but thiamine continued. During the
following 2–5 months the irregular antibodies disappeared.
The girl remained in good health, with normal growth and
psychomotor development until at 20 months rising serum
transaminases led to a liver biopsy that showed the same mild
inflammatory changes as before with the addition of discrete
portal fibrosis, a pattern that resolved slowly over the follow-
ing three years. At 26months of age Hgb had fallen to 101 g/L
and MCV increased to 102 fL. Bone marrow was again meg-
aloblastic and there was disturbed myelopoiesis.
After reintroduction of folic acid, blood and bone marrow
normalised and liver fibrosis decreased. The girl developed
normally, reached high scores on psychological cognitive
tests, and overcame infections, including varicella and influ-
enza, without complications. TRMA was still the presumed
diagnosis and folic acid was again terminated at 11 years.
Four months later respiratory problems with cough appeared
and persisted more than 6 months. At this time sequencing of
SLC19A2 to confirm TRMA was performed but failed to
show any mutations. Since MCV had increased again, folic
acid was reinstituted despite normal Hgb, and thiamine
dropped.
At the age of 21 extensive immunological investigations
were performed while the patient was on folic acid treatment
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demonstrating normal subpopulations of all lymphocytes, and
n o rma l r e s p o n s e s t o p o k ewe e d m i t o g e n a n d
phytohaemagglutin but slightly reduced response to conca-
navalin A (53*103, reference 56–110*103 counts per minute)
and decreased mitogen stimulated IgG production for Epstein-
Barr virus (IgM 500, reference 1000–10,000; IgG 700, refer-
ence 1000–10,000; IgA 100, reference 150–2500).At 22 years
of age and after continuous supplementation with 5 mg folic
acid/day over the last 10 years, the patient has remained in a
very good clinical condition. Hgb, MCV, leukocyte and plate-
let counts have been within normal limits, and bone marrow
shows no major disturbances. She is an athlete at national
level, and has seldom had infections.
Case 4 A girl, born at 37 weeks gestation, birth weight 2550 g,
was breast-fed and thrived up to 6 weeks of age when weight
gain diminished. Moniliasis appeared in her mouth. On routine
check-up at 9 weeks of age anaemia (Hgb 80 g/L) was found,
iron deficiency was suspected and medication started. She was
hospitalised the day after due to vomiting, laboured breathing
and unconsciousness. Severe anaemia (Hgb 56 g/L),
granulocytosis (20.5*109/L) with 7 % immature forms, and
extreme metabolic acidosis were found. She died after a few
hours of intensive care. No cultures were obtained. The only
pathological finding on autopsy was macro-megaloblastic bone
marrow with marked anisocytosis and karyorrhexis.
Myelopoesis was judged to be normal.
Case 5 A boy, born at 37 weeks of gestation, birth weight
2560 g, was breast-fed. At 10 days of age, urine organic acids
were normal. At 6 weeks of age, diminished weight gain, tired-
ness and 7 days of fever up to 39.5 °C led to hospitalisation.
Subsequently, moniliasis in the mouth was found but no other
pathological signs were noted. However, Hgb decreased from
97 to 87 g/L over 1 week, granulocytes decreased to 0.3*109/L,
mean corpuscular volume (MCV) was 98 fL and the platelet
count was high (761*109/L). The bone marrow was megalo-
blastic with anisocytosis and karyorrhexis and the myelopoesis
was affected with prominent giant cells and aberrant nuclei.
Soon after discharge, skin and mucosal lesions appeared
that led to a presumed diagnosis of hand-foot-and-mouth dis-
ease. After a few days of apparent recovery he suddenly
started vomiting, breathed intensively and became uncon-
scious. In hospital, anaemia, leukopenia, thrombocytosis and
extreme metabolic acidosis were noted. Despite intensive
care, he died at 9 weeks of age. At autopsy, general oedema
was found with ascites, hydrothorax, hydropericardium and
lung oedema. The myocardium was diffusely infiltrated by
inflammatory cells, there was interstitial oedema, inflammato-
ry cells also around coronary arteries but no true arteritis, and
foci of pronounced myocardial degeneration and early necro-
sis was found. Inflammatory foci were also seen in lungs,
liver, pancreas and in perivascular areas in the brain. Organic
acids in urine close to death showed high levels of lactate,
fumarate and malate. No etiologic agent was found.
Mutation analysis
Following the identification of the first patient with an MTHF
D1 defect (Watkins et al 2011), the MTHFD1 gene was
screened for coding mutations in patient 2, while patient 3
was screened by whole exome sequencing, which by searching
for folate-related genes rendered only one candidate gene,
MTHFD1. A similar search focused on genes related to thia-
mine metabolism gave no hits. In total, four novel mutations
were found. Patient 2 harbours a missense (c.806C>T;
p.Thr269Ile) and splicing (c.1674G>A) mutation, while pa-
tient 3 harbours a missense (c.146C>T, p.Ser49Phe), of which
the father was a carrier, and nonsense (c.673G>T, p.Glu225*)
mutation, of which the mother was a carrier. Both missense
mutations change highly conserved amino acids in the active-
site of the cyclohydrolase/dehydrogenase domain (Fig. 2)
(Schmidt et al 2000) and are predicted by SIFT (both 3.21,
damaging) (Kumar et al 2009) and Polyphen-2 (both 1.000,
probably damaging) (Adzhubei et al 2010) to be damaging.
Neither mutation was found in the 1000 genomes genetic var-
iation database, while only c.146C>Twas found in the exome
variant server, in 1 allele of 13,005. The splicing variant in
patient 2 codes for a silent mutation (p.Thr558=) but is located
at the last nucleotide of exon 17 and is predicted to affect the
splice donor site of exon 17. This splice site resulted in almost
completely absent mRNA from that allele, since on RT-PCR
experiments the c.806C>T mutation appeared to be homozy-
gous. Confirmation of the splicing defect was performed by
RT-PCR of patient RNA using primers encompassing exons
15–19 (Fig. 3a). In the presence of cycloheximide, which sup-
presses nonsense mediated decay (NMD), a band was
visualised corresponding to a shorter transcript lacking exon
17, which was confirmed by sequencing. This shorter band
was very faint in the absence of cylcoheximide and not seen
in the control. Sequencing of patients 4 and 5 confirmed the
same mutations as their sibling patient 3.
Biochemical determination of MTHFD1 deficiency
Results of biochemical assays performed in fibroblasts of our
patients (patient 2 and 3) as well as in the previous patient
reported by Watkins et al were as follows. MTHFR activity
in all three patients was within the normal range without and
with FAD supplementation (Table 1). Cobalamin synthesis
assay demonstrated slightly decreased methylcobalamin syn-
thesis for patients 2 and 3 (Table 1), consistent with reported
results for the previous patient (Watkins et al 2011). Analysis
of [14C]-propionate incorporation showed normal levels for
the previous patient and patient 2, neither of which was re-
sponsive to OHCbl (Table 1). However, analysis of formation
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of methionine from [14C]-formate demonstrated markedly re-
duced methionine in unsupplemented medium in all three pa-
tient fibroblasts compared to those of wild-type controls
(Fig. 3b). Supplementation of medium with OHCbl (1 mg/
L) had no effect, but addition of folic or folinic acid (each
100 μM) increasedmethionine formation in all patients’ fibro-
blasts, but not in control cells (Fig. 3b). Formation of serine
was also slightly but significantly decreased in fibroblasts
from the previous patient and patient 2, but not in patient 3
compared to control, and did not significantly increase upon
addition of OHCbl, folinic acid or folic acid for any patient
cell line tested (Fig. 3c). An MTHFR deficient cell line
showed similar defects in methionine formation but was not
responsive to OHCbl, folinic acid or folic acid supplementa-
tion (Fig. 3b). However, it had much higher serine formation,
even compared to controls (Fig. 3c).
Discussion
Here we describe four new patients, two still living, with
MTHFD1 deficiency. These patients showed important sim-




Fig. 2 Multiple sequence
alignment of the MTHFC and
MTHFD domains of MTHFD1
across evolution. For clarity only
the first 326 of 935 residues are
shown. Amino acids that are
identical in all organisms listed
are highlighted in black; residues
conserved in most organisms are
in black font. Missense mutations
from the previous patient
(R173C), and patients 2 (T269I)
and 3 (S49F) are pointed out.
Secondary structure elements are
shown above, with α-helices
(coils) and β-sheets (arrows) de-
rived from the structure of the
MTHFS/MTHFD domains of
human MTHFD1 (PDB ID:
1A4I). Sequences are shown for
human (Homo sapiens: NP_





rerio: NP_955823), fruit fly
(Drosophila melanogastor: NP_
731489) and yeast (Saccharomy-
ces cerevisiae: NP_009640).
Alignment was created by
multalin (Corpet 1988) and
visualised by ESPript (Gouet et al
2003)
J Inherit Metab Dis (2015) 38:863–872 869
patient (Table 1). All patients had severe megaloblastic anae-
mia, which seems to be a consistent diagnostic hallmark.
Patient 3 showed pathologic appearance in the bone marrow
at as early as 4 days of age, indicating that this may be an
important early marker of the disease, if tested. While the
previous patient was originally reported to have
methylmalonic aciduria (Watkins et al 2011), a later publi-
cation mentioned normal plasma methylmalonic acid levels
(Keller et al 2013), and methylmalonic aciduria was not seen
in any of our patients. Plasma homocysteine varied from
normal to moderately increased in all living patients and
thus may not be a good biomarker for the disease. Patient
2 showed atypical HUS and severe arterial hypertension
along with microangiopathy and retinopathy. It is of interest
that despite treatment with folinic acid, 5-methyl-THF in the
CSF remained low; however, this did not result in abnormal
cognitive development and we currently do not understand
the mechanism behind it. Patients 4 and 5, in addition to
progressive anaemia, at the same early age very suddenly
developed signs of intensive inflammation, fatal circulatory
shock with severe acidosis, and, in patient 5, widespread
inflammatory lesions in internal organs. The most likely
cause is overwhelming infection, although no agents were
found. The almost identical and rare clinical course is sug-
gestive of an immunological weakness at that phase of life.
Patient 3, their sister, had received folic acid at the age when
her sibs died. She escaped an early infection but had an
episode of autoinflammation at 7 months of age when folic
acid therapy was withdrawn. Together with the SCID seen
in the previous patient, this is suggests that immunological
defects may be an important characteristic of the disease,
although these did not play a role in the history of patient
2. Atypical HUS was found in the previous patient and
patient 2, but not in patients 3, 4 and 5, although the marked
anisocytosis in case 3 might have been a sign of microangi-
opathy, suggesting HUS is also a potential symptom of
MTHFD1 deficiency. Thus, even with these few patients
there is varied clinical presentation; however, haematologi-
cal, immunological and renal symptoms may be prevalent.
MTHFD1 catalyses the 3-step interchange between 5,10-
methylene-THF and formate+THF (Fig. 1). While possible to
function in either direction, stable isotope and whole-body
flux studies suggest that the flow is preferentially in the direc-
tion of incorporation of formate into THF (Tibbetts and
Appling 2010), although recent quantitative flux analysis of
NADPH production suggests it may also flow the other way
(Fan et al 2014). Importantly, the single carbon moeity in 5,
10-methylene-THF is a precursor for both the production of
serine, via transfer onto a glycine molecule by serine
hydroxymethyltransferase, and methionine, via reduction to
5-methyl-THF by MTHFR followed by incorporation into
homocysteine by methionine synthase (Fig. 1). Using [14C]-
formate we measured the synthesis of both [14C]-serine and
[14C]-methionine in our patient cells. We found methionine to
be decreased in each MTHFD1 patient cell line, and serine to
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Fig. 3 RT-PCR demonstrating skipping of exon 17. a. RT-PCR was
performed using primers spanning exons 15–19 on RNA extracted from
either wild-type fibroblasts (control) or MTHD1 patient 2 fibroblasts
without (−CHX) or with (+CHX) pre-incubation of cycloheximide.
Bands were resolved using agarose gel electrophoresis. Expected size
with exon 17: 423 bp; without: 346 bp. Formation of serine and methio-
nine from formate. b. [14C]-methionine formation from [14C]-formate in
fibroblasts fromMTHD1 patients, an MTHFR patient and wild-type con-
trol. Methionine formation of cells from all three MTHFD1 and the
MTHFR patient was decreased compared to control (at least p<0.01).
Folinic acid and folic acid treatment increased MTHFD1 patient fibro-
blast methionine formation (each p<0.001), but not control or MTHFR
(n.s.). c. [14C]-serine formation from [14C]-formate in fibroblasts from
MTHD1 patients, an MTHFR patient and wild-type (control). Serine
formation was decreased in fibroblasts from the previous MTHFD1 pa-
tient and patient 2 compared to control (p<0.05) but not patient 3 (n.s.).
MTHFD1 patient fibroblasts did not increase serine production upon
incubation of OHCbl, folinic acid or folic acid (n.s.), however, in control
fibroblasts serine production was slightly increased with treatment of
OHCbl (p<0.05) and greatly increased with folinic acid and folic acid
(each p<0.001). Untreated MTHFR cells had increased serine formation
compared to controls (p<0.001), which did not significantly increase
upon incubation with OHCbl, folinic acid or folic acid (all n.s.). For (b)
and (c): Control results shownwere performed in parallel withmutants. In
all control cell lines tested so far (n=18), methionine synthesis: 2.73±
0.80 nmol/16 h/mg protein (no OHCbl) and 2.97±1.02 nmol/16 h/mg
protein (OHCbl); serine synthesis: 1.38±0.76 nmol/16 h/mg protein (no
OHCbl) and 1.93±1.12 nmol/16 h/mg protein (OHCbl). n.s., not
significant
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fibroblasts. This is in contrast to MTHFR deficient cells,
which show defects in methionine synthesis only and actually
have increased serine production compared to controls, as
observed here (Fig. 3c) and previously (Fowler et al 1997),
and is consistent with the location of the defect in the pathway
(Fig. 1). It must be noted that the measure of MTHFD1 activ-
ity used here is indirect and not a classical direct assay with
saturating substrate and cofactor concentrations. Nevertheless
this assay has been clearly shown to reliably detect other
remethylation defects (Fowler et al 1997) and in fact may
represent a more appropriate reflection of physiological
conditions.
Our data, therefore, is compatible with production of 5,10-
methylene-THF from formate and THF. Together, these data
provide evidence for disturbance of methionine synthesis in
this folate disorder and suggest that this assay may be used as
a diagnostic tool for the delineation of MTHFD1 deficiency.
Stimulation of methionine synthesis was achieved using
folinic acid in the MTHFD1 cell lines. Folinic acid, also
known as 5-formyl-THF, enters the 1C-THF pathway as 5,
10-methenyl-THF after conversion by 5,10-methenyl-THF
synthetase (Fig. 1), but still requiresMTHFD1 dehydrogenase
activity to form the serine/methionine precursor 5,10-methy-
lene-THF. Therefore, stimulation of methionine production by
folinic acid suggests some activity remains in the patients’
enzymes, and increasing substrate can drive the reaction to-
wards increased product synthesis. Addition of folinic acid
caused increased methionine synthesis in patient cells and
increased serine synthesis in the control, perhaps reflecting
the feedback regulation of cellular methionine synthesis. In-
terestingly, patient fibroblasts also responded to folic acid
treatment, suggesting increasing substrate concentration can
push the reaction forward. Patient 2 responded clinically to
therapy which included folinic acid treatment as well as
hydroxocobalamin and betaine, while patient 3 responded to
therapy which contained, and was eventually limited to, folic
acid. Therefore, folic or folinic acid should be considered as a
possible treatment for MTHFD1 deficiency, provided that re-
sidual activity is present.
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